GPX1 and in situ carcinoma: In ovarian cancer cells, QUE enhanced the CIS sensitivity of the CIS-resistant cell line SKOV-3/CIS by inhibiting the expression of SOD2, catalase (CAT), GPX1, HO-1, Nrf 2, and PI3K/Akt/mTOR (62).